The new work, published in Nature Chemical Biology, tackles a problem that has frustrated the apoptosis field since BAX was first implicated in ischemic injury: the protein is a moving target. In healthy cells, BAX lounges in the cytosol as an inactive monomer, its lethal membrane-penetrating helices tucked away inside its own structure. Only when death signals accumulate does BAX undergo a dramatic conformational transformation, exposing its N-terminus, unfurling its ninth alpha helix, and migrating to the mitochondrial outer membrane, where it oligomerizes into pores. Small molecules that bind the resting state have been described before, but they tend to be weak, poorly characterized, or reactive with many unrelated proteins, making them unreliable tools and even less reliable medicines.

The team behind the new study took a different approach: rather than hunting for a generic binder, they engineered a covalent warhead aimed at a specific cysteine residue on the surface of inactive BAX. Covalent inhibitors have enjoyed a renaissance in recent years, most famously in the form of acrylamide-based drugs that target a non-catalytic cysteine in EGFR-mutant lung cancer. The strategy offers the allure of prolonged target engagement at low drug concentrations, but it carries a well-known risk: off-target reactivity with the many cysteine-rich proteins floating in any cell. The challenge, therefore, was to design a ligand whose reactivity is only unleashed in the precise geometric context of the BAX binding pocket.

That is where the concept of enantioselectivity becomes central. Small drug-like molecules typically exist as two enantiomers, mirror-image forms that are chemically identical in an achiral test tube but profoundly different in the chiral environment of a living cell. Enzymes, receptors, and protein binding pockets distinguish between these mirror images with exquisite sensitivity, often binding one form tightly while ignoring the other. The researchers exploited this principle twice over: first by synthesizing both enantiomers of their candidate inhibitor and then by demonstrating that only one of them engages BAX efficiently, while the opposite enantiomer is essentially inert. This one-handed specificity is a hallmark of a well-behaved chemical probe and stands in sharp contrast to earlier BAX inhibitors whose activity could not be cleanly separated from nonspecific protein damage.

The design process began with structural analysis of the inactive BAX monomer, using prior nuclear magnetic resonance structures and molecular docking to identify a pocket adjacent to a reactive cysteine. The team then iterated through a series of analogues, tuning the electrophilic warhead and the surrounding scaffold until they achieved a compound that reacts with BAX rapidly and selectively in competition assays against a broad panel of cysteine-containing proteins. Chemoproteomic experiments in cell lysates confirmed the selectivity on a proteome-wide scale, showing that the compound’s covalent footprint is dominated by BAX rather than by the hundreds of other cysteine residues available for reaction. This kind of global reactivity profiling has become the gold standard for validating covalent chemistry, and its successful application here lends substantial credibility to the probe.

With a selective inhibitor in hand, the researchers turned to functional testing. In cell culture, the compound protected cells from apoptotic death provoked by a variety of stresses, and the protection was abolished when BAX was removed or when a non-reactive analogue was substituted, establishing that the cytoprotective effect runs through the intended target. Biochemical assays showed that the covalently modified BAX can no longer expose its membrane-inserting helix or translocate to mitochondria in response to activating signals, effectively locking the protein in its harmless resting conformation. The modification also prevented BAX oligomerization, the downstream step that converts individual protein molecules into the pore-forming assemblies that rupture the mitochondrial membrane and release cytochrome c.

The most consequential experiments, however, were performed in living animals. In a mouse model of ischemia-reperfusion injury, a scenario that mirrors the cellular damage that follows a heart attack or stroke, administration of the active enantiomer significantly reduced tissue damage compared with vehicle controls. Critically, the mirror-image enantiomer, which lacks BAX reactivity in vitro, provided no protection, a rigorous in vivo control that ties the therapeutic benefit directly to the covalent engagement of BAX. Pharmacokinetic measurements confirmed that the compound reaches relevant tissues at concentrations sufficient to modify the target, and the treated animals tolerated the drug without overt toxicity, an encouraging early signal for a strategy that modifies a protein involved in fundamental cellular quality control.

Experts in the apoptosis field have long debated whether inhibiting BAX systemically is safe or even desirable, given the protein’s role in eliminating damaged or potentially cancerous cells. The new study does not resolve that debate, but it sharpens the terms of the discussion. Because the inhibitor is covalent and long-acting, dosing regimens could in principle be tailored to acute, short-term scenarios, such as the hours surrounding reperfusion therapy after a myocardial infarction, where transient BAX inhibition might salvage tissue without the long-term cancer risks that chronic suppression might entail. The authors’ demonstration that a single enantiomer drives the entire pharmacological effect also suggests that medicinal chemistry optimization can proceed with confidence, since the inactive mirror image provides a built-in negative control for every future experiment.

The work also carries broader lessons for chemical biology. Covalent inhibitors were once viewed as liabilities to be engineered out of drug candidates; today they are a deliberate design choice, provided that selectivity is demonstrated rigorously. The BAX program illustrates the full pipeline: structural insight to identify a ligandable site, warhead tuning to balance reactivity and selectivity, enantiomer pairing to isolate specific from nonspecific effects, chemoproteomics to survey the proteome, and animal models to test whether the molecular mechanism translates into tissue-level protection. Each step reinforces the others, and the resulting probe is far more than a tool; it is a proof of concept that a notoriously difficult, conformationally dynamic protein can be drugged with precision.

Looking ahead, the researchers and their colleagues face the familiar gauntlet of translation: optimizing potency and pharmacokinetics, assessing safety across longer time horizons, and identifying the clinical settings where BAX inhibition offers the greatest benefit at the least risk. Beyond ischemic injury, candidates include neurodegenerative conditions in which mitochondrial apoptosis contributes to neuronal loss, and organ transplantation, where protecting donor tissue from programmed death could extend viability and improve outcomes. Whatever the ultimate therapeutic destination, the demonstration that an enantioselective covalent inhibitor of BAX can confer cytoprotection in vivo marks a milestone in the long campaign to control the machinery of cell death, and it hands the field a chemical instrument of unprecedented specificity for dissecting BAX biology in health and disease.

Subject of Research: Development of an enantioselective covalent small-molecule inhibitor of the pro-apoptotic protein BAX that prevents mitochondrial apoptosis and provides cytoprotection in vivo.

Article Title: An enantioselective covalent inhibitor of BAX confers cytoprotection in vivo

Article References: An enantioselective covalent inhibitor of BAX confers cytoprotection in vivo. (n.d.). https://doi.org/10.1038/s41589-026-02297-9

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02297-9

Keywords: BAX, apoptosis, covalent inhibitor, enantioselectivity, mitochondria, cytoprotection, ischemia-reperfusion injury, chemical biology, drug design, chemoproteomics, Nature Chemical Biology, cell death